# EDGAR Filing Document

**Accession Number:** 0001843594
**File Stem:** 0000897069-23-000094
**Filing Date:** 2023-2
**Character Count:** 13303
**Document Hash:** 19ccf4b49c70b9be27b7c5d07e61d193
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000897069-23-000094.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0000897069-23-000094

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cambrian BioPharma Inc
- **CENTRAL INDEX KEY:** 0001797409
- **IRS NUMBER:** 842985609
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93965
- **FILM NUMBER:** 23619941

**BUSINESS ADDRESS:**
- **STREET 1:** 228 PARK AVENUE S.
- **STREET 2:** #66643
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003
- **BUSINESS PHONE:** (516) 962-3186

**MAIL ADDRESS:**
- **STREET 1:** 228 PARK AVENUE S.
- **STREET 2:** #66643
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cambrian BioPharma Inc.
- **DATE OF NAME CHANGE:** 20191219
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Peyer James
- **CENTRAL INDEX KEY:** 0001843594

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**MAIL ADDRESS:**
- **STREET 1:** C/O SENSEI BIOTHERAPEUTICS, INC.
- **STREET 2:** 1405 RESEARCH BLVD., STE. 125
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

#### UNITED STATES

#### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### SCHEDULE 13G

#### Under the Securities Exchange Act of 1934

#### (Amendment No. 2) \*<br>

#### <br>

<u>Sensei Biotherapeutics, Inc.</u>

(Name of Issuer)

<u>Common Stock, $0.0001 par value per share</u>

(Title of Class of Securities)

<u>81728A 108</u>

(CUSIP Number)

<u>December 31, 2022</u>

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br>

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp; **1** | NAME OF REPORTING PERSONS<br>James Peyer | NAME OF REPORTING PERSONS<br>James Peyer | NAME OF REPORTING PERSONS<br>James Peyer | NAME OF REPORTING PERSONS<br>James Peyer |
| &nbsp;&nbsp; **2** | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) ☐<br> (b) ☐ |
| &nbsp;&nbsp; **3** | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| &nbsp;&nbsp; **4** | CITIZENSHIP OR PLACE OF ORGANIZATION<br>United States | CITIZENSHIP OR PLACE OF ORGANIZATION<br>United States | CITIZENSHIP OR PLACE OF ORGANIZATION<br>United States | CITIZENSHIP OR PLACE OF ORGANIZATION<br>United States |
| **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **5** | SOLE VOTING POWER<br>0 | SOLE VOTING POWER<br>0 |
| **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **6** | SHARED VOTING POWER<br>0 | SHARED VOTING POWER<br>0 |
| **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **7** | SOLE DISPOSITIVE POWER<br>0 | SOLE DISPOSITIVE POWER<br>0 |
| **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **8** | SHARED DISPOSITIVE POWER<br>0 | SHARED DISPOSITIVE POWER<br>0 |
| &nbsp;&nbsp; **9** | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>0 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>0 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>0 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>0 |
| **10** | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | &nbsp;&nbsp;&nbsp;&nbsp; □<br>|
| **11** | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>0.0% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>0.0% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>0.0% | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>0.0% |
| **12** | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>IN | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>IN | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>IN | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>IN |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp; **1** | NAME OF REPORTING PERSONS<br>Cambrian BioPharma Inc. | NAME OF REPORTING PERSONS<br>Cambrian BioPharma Inc. | NAME OF REPORTING PERSONS<br>Cambrian BioPharma Inc. | NAME OF REPORTING PERSONS<br>Cambrian BioPharma Inc. |
| &nbsp;&nbsp; **2** | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) ☐<br> (b) ☐ |
| &nbsp;&nbsp; **3** | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| &nbsp;&nbsp; **4** | CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware |
| **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **5** | SOLE VOTING POWER<br>5,235,956 (1) | SOLE VOTING POWER<br>5,235,956 (1) |
| **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **6** | SHARED VOTING POWER<br>0 | SHARED VOTING POWER<br>0 |
| **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **7** | SOLE DISPOSITIVE POWER<br>5,235,956 (1) | SOLE DISPOSITIVE POWER<br>5,235,956 (1) |
| **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH** | **8** | SHARED DISPOSITIVE POWER<br>0 | SHARED DISPOSITIVE POWER<br>0 |
| &nbsp;&nbsp; **9** | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>5,235,956 (1) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>5,235,956 (1) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>5,235,956 (1) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>5,235,956 (1) |
| **10** | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | &nbsp;&nbsp;&nbsp;&nbsp; □<br>|
| **11** | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>17.0%<sup>(2)</sup> | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>17.0%<sup>(2)</sup> | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>17.0%<sup>(2)</sup> | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>17.0%<sup>(2)</sup> |
| **12** | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>CO | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>CO | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>CO | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>CO |

---

---

| | |
|:---|:---|
| (1)<br>(2)<br>| Includes unvested restricted stock units. Excludes unexercised stock options to purchase shares of comon stock. <br>The percent ownership calculated is based upon an aggregate of 30,720,291 shares outstanding as of November 4, 2022. |

---

------

Item 1(a). <u>Name of Issuer</u>:

Sensei Biotherapeutics, Inc.

Item 1(b). <u>Address of Issuer's Principal Executive Offices</u>:

1405 Research Blvd, Suite 125, Rockville, MD 20850

Item 2(a). <u>Name of Person Filing</u>:

James Peyer and Cambrian BioPharma Inc.

Item 2(b). <u>Address of Principal Business Office or, if none, Residence</u>:

The business address of each of James Peyer and Cambrian BioPharma Inc. is 228 Park Avenue S. #66643, New York, New York 10003.

Item 2(c). <u>Citizenship</u>:

Mr. Peyer is a United States citizen. Cambrian BioPharma Inc. is a Delaware corporation.

Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, $0.0001 par value per share

Item 2(e). <u>CUSIP Number</u>:

81728A 108

Item 3. <u>If this statement is filed pursuant to sections 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a</u>:

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k) [ ] Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

------

Item 4. <u>Ownership</u>:

(a) Amount Beneficially Owned:

Consists of 5,235,956 shares of common stock and excludes 50,736 stock options to purchase shares of common stock. All such securities are held by Cambrian Biopharma Inc. Cambrian is a Delaware corporation and Mr. Peyer serves as Cambrian's Chief Executive Officer. In such capacity Mr. Peyer may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

(b) Percent of Class: 17.0%

<br> (c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote: 5,235,956

(ii) shared power to vote or to direct the vote: 0

<br> (iii) sole power to dispose or to direct the disposition of: 5,235,956

<br> (iv) shared power to dispose or to direct the disposition of: 0

### Item 5. <u>Ownership of Five Percent or Less of a Class</u>:

Not Applicable

### Item 6. <u>Ownership of More than Five Percent on Behalf of Another Person</u>:

Not Applicable

Item 7. <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person</u>:

Not Applicable

Item 8. <u>Identification and Classification of Members of the Group</u>:

Not Applicable

Item 9. <u>Notice of Dissolution of Group</u>:

Not Applicable

Item 10. <u>Certification</u>:

Not Applicable

------

#### SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February __, 2023

/s/ James Peyer

Cambrian BioPharma Inc.

Name: James Peyer

Title:&nbsp;&nbsp;&nbsp;&nbsp; CEO <br>